Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease

IMPORTANCE: The latest guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD). Despite this, overall use of these 2 drug classes...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jing, Feldman, Robert, Callaway Kim, Katherine, Rothenberger, Scott, Korytkowski, Mary, Hernandez, Inmaculada, Gellad, Walid F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261995/
https://www.ncbi.nlm.nih.gov/pubmed/37307000
http://dx.doi.org/10.1001/jamanetworkopen.2023.17886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261995/
https://www.ncbi.nlm.nih.gov/pubmed/37307000
http://dx.doi.org/10.1001/jamanetworkopen.2023.17886

Ejemplares similares